Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
Significance: Current therapies for pulmonary fibrosis (PF) focus on slowing disease progression and reducing functional decline in patients by dampening the activation of fibroblasts and other implicated cells. There is a need for strategies that target the essential cells and signaling pathways involved in disease pathogenesis. Monocyte-derived macrophages (Mo-Macs) are known to express profibrotic genes and are involved in the pathogenesis of PF. Our results show that engineered mannosylated albumin nanoparticles specifically targeted disease-inducing Mo-Macs, and further, that nanoparticles efficiently delivered small-interfering RNA against profibrotic cytokine tumor growth factor β1 to prevent bleomycin-induced lung fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, mannose-modified albumin nanoparticles delivering TGF-b1 siRNA have been shown to effectively attenuate pulmonary fibrosis severity in murine models (157).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [157]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aran, D., Looney, A. P., Liu, L., Wu, E., Fong, V., Hsu, A., Chak, S., Naikawadi, R. P., Wolters, P. J., Abate, A. R., et al. (2019) · Nature Immunology · doi:10.1038/s41590-018-0276-y · Cited by 4,984 · cited 9×
“Cx3cr1CreERT2 mice were administered tamoxifen (75 mg/kg body weight) via intraperitoneal injection starting before 1 wk of bleomycin instillation and continuing every other day throughout the treatment for Cre induction (17).”
BackgroundMethodResultInfluentialOrecchioni, M., Ghosheh, Y., Pramod, A. B., & Ley, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01084 · Cited by 2,063
Fibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765 · cited 1×
“PF has a median survival of 2 to 5 y from time of diagnosis (3).”
BackgroundAlbumin-based nanoparticles as potential controlled release drug delivery systems
Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.031 · Cited by 1,520
Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span
Misharin, A. V., Morales-Nebreda, L., Reyfman, P. A., Cuda, C. M., Walter, J. M., McQuattie-Pimentel, A. C., Chen, C.-I., Anekalla, K. R., Joshi, N., Williams, K. J. N., et al. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20162152 · Cited by 1,133 · cited 7×
“Mo-Macs in response to inflammatory cues also migrated into the lung airspace and transitioned into de novo AMs, referred to as Mo-AMs (12, 17).”
BackgroundInfluentialPulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy
George, P. M., Wells, A. U., & Jenkins, R. G. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30225-3 · Cited by 1,085
TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease
Willis, B. C., & Borok, Z. (2007) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00163.2007 · Cited by 1,042 · cited 1×
“The macrophage populations in lungs generated the cytokines TGFβ1, PDGFα, and VEGF (10) that promoted differentiation of fibroblasts into myofibroblasts and increased production of extracellular matrix (ECM) proteins (14, 15).”
BackgroundMoeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Flow Cytometric Analysis of Macrophages and Dendritic Cell Subsets in the Mouse Lung
Misharin, A. V., Morales-Nebreda, L., Mutlu, G. M., Budinger, G. R. S., & Perlman, H. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0086ma · Cited by 838 · cited 1×
“elevated during both acute and fibrotic phases in PF models (25).”
BackgroundPulmonary fibrosis: pathogenesis, etiology and regulation
Wilson, M. S., & Wynn, T. A. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.85 · Cited by 822 · cited 1×
“PF pathogenesis involves the activation of innate and adaptive immune pathways releasing an array of growth factors and proinflammatory cytokines interleukin (IL)-4, IL-13, and tumor growth factor (TGF)β1 in response to which lung fibroblasts and macrophages acquire the profibrogenic phenotype and become resistant to…”
BackgroundMurine models of pulmonary fibrosis
Moore, B. B., & Hogaboam, C. M. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00313.2007 · Cited by 796 · cited 1×
“induces PF (19, 29) during a 7-d time course experimental,”
MethodProtein-Based Nanoparticles as Drug Delivery Systems
Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070604 · Cited by 619 · cited 1×
“Protein-based nanocarriers, such as ANPs, were used because of their safety profile and relevance to clinical translation (33).”
Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis
Chen, W., Schilperoort, M., Cao, Y., Shi, J., Tabas, I., & Tao, W. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00629-x · Cited by 518 · cited 1×
“chemical stability of nanoparticle-encapsulated therapeutics (20).”
Ly6Chi monocytes direct alternatively activated profibrotic macrophage regulation of lung fibrosis
Gibbons, M. A., MacKinnon, A. C., Ramachandran, P., Dhaliwal, K., Duffin, R., Phythian-Adams, A. T., van Rooijen, N., Haslett, C., Howie, S. E., Simpson, A. J., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201010-1719oc · Cited by 466 · cited 1×
“Deletion of these genes or ablation of Mo-Macs ameliorated lung fibrosis in mouse models (18).”
BackgroundTime course of bleomycin‐induced lung fibrosis
Izbicki, G., Segel, M. J., Christensen, T. G., Conner, M. W., & Breuer, R. (2002) · International Journal of Experimental Pathology · doi:10.1046/j.1365-2613.2002.00220.x · Cited by 447
Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.170 · Cited by 402 · cited 2×
“Beyond the limited efficacy of dampening the activation of fibroblasts with drugs such as Pirfenidone or Nintedanib, there is no approach targeting the specific diseaseinducing macrophage population (1).”
BackgroundProtection from Pulmonary Fibrosis in the Absence of CCR2 Signaling
Moore, B. B., Paine, R., Christensen, P. J., Moore, T. A., Sitterding, S., Ngan, R., Wilke, C. A., Kuziel, W. A., & Toews, G. B. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.8.4368 · Cited by 371
Yu, Y.-R. A., O’Koren, E. G., Hotten, D. F., Kan, M. J., Kopin, D., Nelson, E. R., Que, L., & Gunn, M. D. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150606 · Cited by 361 · cited 1×
“For biodistribution analysis, the different immune cells were gated following a published protocol (55).”
MethodImmune mechanisms in pulmonary fibrosis
Kolahian, S., Fernandez, I. E., Eickelberg, O., & Hartl, D. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2016-0121tr · Cited by 349 · cited 5×
“Induction of fibrosis involves Mo-AM–mediated release of profibrotic cytokines that activate endothelial cells and fibroblasts toward profibrotic phenotype leading to fibrosis (10).”
BackgroundInfluentialJoshi, N., Watanabe, S., Verma, R., Jablonski, R. P., Chen, C.-I., Cheresh, P., Markov, N. S., Reyfman, P. A., McQuattie-Pimentel, A. C., Sichizya, L., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.00646-2019 · Cited by 344 · cited 1×
“Mo-AMs localized in the fibrotic niche are believed to induce the disease through unchecked release of fibrogenic cytokines, such as TGFβ1 (17, 43).”
BackgroundPrevention of vascular inflammation by nanoparticle targeting of adherent neutrophils
Wang, Z., Li, J., Cho, J., & Malik, A. B. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.17 · Cited by 300 · cited 2×
“The ANPs were synthesized following a desolvation technique using Bovine Serum Albumin (BSA, molecular mass 66,000 Da; Sigma) with modification to an earlier protocol (32).”
MethodSelf-citationTao, W., Yurdagul, A., Kong, N., Li, W., Wang, X., Doran, A. C., Feng, C., Wang, J., Islam, M. A., Farokhzad, O. C., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1063 · Cited by 255 · cited 1×
“MANPs loaded with siRNA have the potential of delivering siRNA by evading rapid blood clearance via nuclease degradation and through poor endosomal escape of the siRNA (38, 48).”
BackgroundZhao, P., Wang, Y., Kang, X., Wu, A., Yin, W., Tang, Y., Wang, J., Zhang, M., Duan, Y., & Huang, Y. (2018) · Chemical Science · doi:10.1039/c7sc04853j · Cited by 248 · cited 1×
“Thus, we coated ANPs with D-mannose by opening the aldehyde groups at low pH and high temperature and then reacting the activated mannose with free amine groups of ANPs (35).”
MethodSurvival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis
Thabut, G., Mal, H., Castier, Y., Groussard, O., Brugière, O., Marrash-Chahla, R., Lesèche, G., & Fournier, M. (2003) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(03)00600-7 · Cited by 245
Hu, G., Guo, M., Xu, J., Wu, F., Fan, J., Huang, Q., Yang, G., Lv, Z., Wang, X., & Jin, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01998 · Cited by 237
Does tissue imprinting restrict macrophage plasticity?
Guilliams, M., & Svedberg, F. R. (2021) · Nature Immunology · doi:10.1038/s41590-020-00849-2 · Cited by 232 · cited 1×
“Other possibilities could involve the role of CX3CR1 SiglecF macrophages in epithelial–mesenchymal transition believed to contribute to lung fibrosis (51) and the inhibition of NF-κB–mediated profibrotic gene expression induced by CD148 phosphatase in fibroblasts (52).”
BackgroundMBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program
Wang, Y., Zhang, L., Wu, G.-R., Zhou, Q., Yue, H., Rao, L.-Z., Yuan, T., Mo, B., Wang, F.-X., Chen, L.-M., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb6075 · Cited by 227 · cited 3×
“A liposomal approach has also been used to target a profibrotic macrophage population by depleting the cellsurface methyl-CpG–binding domain 2 (MBD2) (4).”
BackgroundMethodInfluentialHealing after COVID-19: are survivors at risk for pulmonary fibrosis?
McDonald, L. T. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00238.2020 · Cited by 223
Deletion of c-FLIP from CD11bhi Macrophages Prevents Development of Bleomycin-induced Lung Fibrosis
McCubbrey, A. L., Barthel, L., Mohning, M. P., Redente, E. F., Mould, K. J., Thomas, S. M., Leach, S. M., Danhorn, T., Gibbings, S. L., Jakubzick, C. V., et al. (2018) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0154oc · Cited by 195 · cited 3×
“Transcriptomic and gene-expression analysis revealed that Mo-Macs displayed not only down-regulation of genes typically expressed in monocytes and up-regulation of genes expressed in AMs, but also markedly increased the expression of proinflammatory and profibrotic genes (11, 17, 19).”
BackgroundMicrocystin-LR ameliorates pulmonary fibrosis via modulating CD206+ M2-like macrophage polarization
Wang, J., Xu, L., Xiang, Z., Ren, Y., Zheng, X., Zhao, Q., Zhou, Q., Zhou, Y., Xu, L., & Wang, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2329-z · Cited by 171
Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer
Xu, J., Liu, Y., Li, Y., Wang, H., Stewart, S., der Jeught, K. V., Agarwal, P., Zhang, Y., Liu, S., Zhao, G., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-019-0381-6 · Cited by 161 · cited 2×
“MANPs loaded with siRNA have the potential of delivering siRNA by evading rapid blood clearance via nuclease degradation and through poor endosomal escape of the siRNA (38, 48).”
BackgroundLiu, S., Liu, C., Lv, X., Cui, B., Yan, J., Li, Y., Li, K., Hua, F., Zhang, X., Yu, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.06.008 · Cited by 137
Erratum: Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease
Mora, A. L., Rojas, M., Pardo, A., & Selman, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.225 · Cited by 128
Inhibitors of clathrin-dependent endocytosis enhance TGFβ signaling and responses
Chen, C.-L., Hou, W.-H., Liu, I.-H., Hsiao, G., Huang, S. S., & Huang, J. S. (2009) · Journal of Cell Science · doi:10.1242/jcs.038729 · Cited by 124 · cited 1×
“Uptake via receptor-mediated endocytosis of MANPs was evident using monodansyl cadaverine, a clathrin-mediated endocytosis inhibitor (37), which prevented MANP internalization in a concentration-dependent manner (Fig.”
MethodMacrophage metabolic reprogramming during chronic lung disease
Ogger, P. P., & Byrne, A. J. (2021) · Mucosal Immunology · doi:10.1038/s41385-020-00356-5 · Cited by 118
Reprogramming of profibrotic macrophages for treatment of bleomycin‐induced pulmonary fibrosis
Zhang, F., Ayaub, E. A., Wang, B., Puchulu‐Campanella, E., Li, Y., Hettiarachchi, S. U., Lindeman, S. D., Luo, Q., Rout, S., Srinivasarao, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.202012034 · Cited by 108 · cited 3×
“We also observed significant increases in the expression of profibrotic mediators TGFβ1, IL-1β, and Arg1 (27) on both day 7 and day 15 in the MANP+ Mo-AMs, (Fig.”
BackgroundInfluentialGauldie, J., Sime, P. J., Xing, Z., Marr, B., & Tremblay, G. M. (1999) · Current topics in pathology · doi:10.1007/978-3-642-58456-5_5 · Cited by 105 · cited 1×
“The macrophage populations in lungs generated the cytokines TGFβ1, PDGFα, and VEGF (10) that promoted differentiation of fibroblasts into myofibroblasts and increased production of extracellular matrix (ECM) proteins (14, 15).”
BackgroundMonocytes and macrophages as nanomedicinal targets for improved diagnosis and treatment of disease
Lameijer, M. A., Tang, J., Nahrendorf, M., Beelen, R. H. J., & Mulder, W. J. M. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2013.819216 · Cited by 97
Vascular permeability in the fibrotic lung
Probst, C. K., Montesi, S. B., Medoff, B. D., Shea, B. S., & Knipe, R. S. (2020) · European Respiratory Journal · doi:10.1183/13993003.00100-2019 · Cited by 94
Redente, E. F., Chakraborty, S., Sajuthi, S. P., Black, B. P., Edelman, B., Seibold, M. A., & Riches, D. W. H. (2020) · JCI Insight · doi:10.1172/jci.insight.141618 · Cited by 72 · cited 1×
“Finally, the MANP-targeted macrophages may inactivate Fas signaling that leads to fibroblast survival and persistence and continued profibrotic functions of lung fibroblasts (53).”
BackgroundSelf-citationCerium oxide nanoparticle delivery of microRNA-146a for local treatment of acute lung injury
Niemiec, S. M., Hilton, S. A., Wallbank, A. M., Azeltine, M., Louiselle, A. E., Elajaili, H. B., Allawzi, A. M., Xu, J., Mattson, C., Dewberry, L. C. K., et al. (2021) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2021.102388 · Cited by 65 · cited 1×
“These include cerium oxide nanoparticle delivery of microRNA-146a for treatment of acute lung injury and fibrosis (45).”
BackgroundCD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis
Tsoyi, K., Liang, X., Rossi, G. D., Ryter, S. W., Xiong, K., Chu, S. G., Liu, X., Ith, B., Celada, L. J., Romero, F., et al. (2021) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202008-3100oc · Cited by 63 · cited 1×
“Other possibilities could involve the role of CX3CR1 SiglecF macrophages in epithelial–mesenchymal transition believed to contribute to lung fibrosis (51) and the inhibition of NF-κB–mediated profibrotic gene expression induced by CD148 phosphatase in fibroblasts (52).”
BackgroundDysregulated overexpression of Sox9 induces fibroblast activation in pulmonary fibrosis
Gajjala, P. R., Kasam, R. K., Soundararajan, D., Sinner, D., Huang, S. K., Jegga, A. G., & Madala, S. K. (2021) · JCI Insight · doi:10.1172/jci.insight.152503 · Cited by 62 · cited 1×
“The protection may thus be the result of disruption of signaling interaction between the targeted CX3CR1 SiglecF macrophages and dampening of the proximal fibrogenic fibroblasts by counteracting dysregulated transcriptional programs in fibroblasts (50).”
BackgroundNanomedicines for dysfunctional macrophage-associated diseases
He, H., Ghosh, S., & Yang, H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.032 · Cited by 53
The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?
Ryerson, C. J., & Kolb, M. R. J. (2018) · European Respiratory Journal · doi:10.1183/13993003.02420-2017 · Cited by 51
Wong, S. W., Tamatam, C. R., Cho, I. S., Toth, P. T., Bargi, R., Belvitch, P., Lee, J. C., Rehman, J., Reddy, S. P., & Shin, J.-W. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00740-x · Cited by 51 · cited 2×
“15) was used to quantify histology images by machine learning (54).”
MethodSelf-citationBordag, N., Biasin, V., Schnoegl, D., Valzano, F., Jandl, K., Nagy, B. M., Sharma, N., Wygrecka, M., Kwapiszewska, G., & Marsh, L. M. (2020) · iScience · doi:10.1016/j.isci.2020.101819 · Cited by 47 · cited 7×
“Temporal analysis of lung tissue responses have previously been shown to demonstrate an immediate increase in inflammation and number of Mo-AMs at day 3 and a decline after 14 d postbleomycin instillation (19).”
BackgroundMethodInfluentialTargeting macrophages using nanoparticles: a potential therapeutic strategy for atherosclerosis
Zang, X., Cheng, M., Zhang, X., & Chen, X. (2021) · Journal of Materials Chemistry B · doi:10.1039/d0tb02956d · Cited by 39
Uriarte, S. M., Jog, N. R., Luerman, G. C., Bhimani, S. J., Ward, R. A., & McLeish, K. R. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00454.2008 · Cited by 34 · cited 1×
“(D and E) Monodansyl cadaverine, inhibitor of receptor-mediated endocytosis (56), in a concentration-dependent manner prevented MANP internali-”
BackgroundLiu, S., Liu, C., Lv, X., Cui, B., Yan, J., Li, Y., Li, K., Hua, F., Zhang, X., Yu, J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.09.009 · Cited by 30
Purification and characterization of the d-mannose receptor from J774 mouse macrophage cells
Blum, J. S., Stahl, P. D., Díaz, R., & Fiani, M. L. (1991) · Carbohydrate Research · doi:10.1016/s0008-6215(00)90605-0 · Cited by 29
Zou, R., Gui, X., Ji, Z., Tian, Y., Liu, X., Tian, M., Chen, T., Wu, H., Chen, J., Dai, J., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106732 · Cited by 27
Lu, Y., Liang, L., Cheng, P., Xiong, L., Wang, M., Song, L., Yu, F., He, X., Xiong, L., Wang, X., et al. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00436.2020 · Cited by 18 · cited 1×
“This was possible since lung fibrosis is accompanied by lung vascular injury (leakiness of the endothelial barrier) which persists in case of progressive fibrotic diseases as in idiopathic PF (47, 49).”
BackgroundZou, H., & Li, S.-Q. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00566-4 · Cited by 17
Pintado‐Berninches, L., Montes‐Worboys, A., Manguán-García, C., Arias‐Salgado, E. G., Serrano, A., Fernández-Varas, B., Guerrero, R., Iarriccio, L., Planas‐Cerezales, L., Güenechea, G., et al. (2021) · The FASEB Journal · doi:10.1096/fj.202001160rr · Cited by 13 · cited 1×
“PEI nanoparticles incorporating GSE4 were delivered via airway postbleomycin, which increased telomerase activity and decreased DNA damage and showed antifibrotic activity (46).”
BackgroundMcLellan, T., George, P. M., Ford, P., Backer, J. D., Holsbeke, C. S. V., Mignot, B., Screaton, N. J., Ruggiero, A., & Thillai, M. (2020) · ERJ Open Research · doi:10.1183/23120541.00290-2019 · Cited by 11
Research works printed but not linked: 1
- Health NIo, Idiopathic Pulmonary Fibrosis Frequency (US National Library of Medicine, 2020).
Cited by
Biology of lung macrophages in health and disease
Aegerter, H., Lambrecht, B. N., & Jakubzick, C. V. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.010 · Cited by 621
Malainou, C., Abdin, S. M., Lachmann, N., Matt, U., & Herold, S. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170501 · Cited by 201
“Reprogramming of AMs and targeting of fibrosis-related intracellular pathways in favor of a coordinated and accelerated epithelial repair, therefore, emerge as potential therapeutic strategies for a clinical phenotype with remarkably limited treatment options (90, 95, 96).”
BackgroundLipid Nanoparticles Optimized for Targeting and Release of Nucleic Acid
Jia, Y., Wang, X., Li, L., Li, F., Zhang, J., & Liang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305300 · Cited by 171
Enomoto, Y., Katsura, H., Fujimura, T., Ogata, A., Baba, S., Yamaoka, A., Kihara, M., Abe, T., Nishimura, O., Kadota, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40617-y · Cited by 132
Monocytes and macrophages: emerging mechanisms and novel therapeutic targets in pulmonary fibrosis
Perrot, C. Y., Karampitsakos, Τ., & Herazo‐Maya, J. D. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00302.2023 · Cited by 104
Metadata
- Authors
- Singh, A., Chakraborty, S., Wong, S. W., Hefner, N. A., Stuart, A., Qadir, A. S., Mukhopadhyay, A., Bachmaier, K., Shin, J.-W., Rehman, J., & Malik, A. B.
- Affiliations
- University of Illinois Chicago (US)
- Corresponding author
- Malik, Asrar B.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2022-04-04
- Volume
- 119
- Issue
- 15
- Pages
- e2121098119-e2121098119
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC9169714
- OpenAlex
- W4224117100
- Cited by
- 107
- References
- 57
- Citations by year
- 2026: 22 · 2025: 34 · 2024: 24 · 2023: 20 · 2022: 7
- FWCI
- 13.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Heart, Lung, and Blood Institute (T32HL007829, R41HL126456, R42HL126456, P01HL151327, R01HL141255)
- HHS | NIH | National Institute of General Medical Sciences (R01GM141147)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- pulmonary fibrosis, macrophage targeting, TGF-β1, siRNA delivery, monocyte-derived macrophages, alveolar macrophages, interstitial macrophages, nanoparticle uptake, extracellular matrix remodeling, antifibrotic therapy
- MeSH terms
- Mannose Receptor, Animals, Bleomycin, Disease Models, Animal, Lymphotoxin-alpha, Mice, Inbred C57BL, Pulmonary Fibrosis, Macrophages, Alveolar, RNA, Small Interfering, Mice, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.